Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Thaddeus Oneill

Plastic Surgery Sheboygan, WI Medical Doctor

NPI 1699714873 CMS profile 952311

2414 Kohler Memorial Dr, Sheboygan, WI 53081

Open in the dashboard

General payments

$840

14 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thaddeus Oneill of Sheboygan, WI is reported in the CMS Open Payments database as having received $840 across 14 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 32nd percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $492 5
2024 General $221 2
2023 General $17 1
2022 General $49 2
2021 General $62 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thaddeus Oneill
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Thaddeus Oneill were reported at $492. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Thaddeus Oneill Plastic Surgery median Middle half National median
2019 $0 $371 $122–$1,483 $163
2020 $0 $158 $52–$438 $114
2021 $62 $249 $87–$752 $132
2022 $49 $274 $102–$793 $149
2023 $17 $299 $113–$891 $160
2024 $221 $361 $124–$1,062 $164
2025 $492 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Kerecis Limited $458 3 payments
  2. Mentor Worldwide LLC $145 3 payments
  3. Integra LifeSciences Corporation $138 2 payments
  4. Galderma Laboratories, L.P. $53 3 payments
  5. Sientra, Inc. $30 2 payments
  6. Acera Surgical, Inc. $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $840 14 payments
Products named General payments · program years 2021–2025
  1. Kerecis SurgiClose Wound Care $458 3 payments
  2. Kerecis SurgiClose Wound Care $458 3 payments
  3. Kerecis SurgiClose Wound Care $458 3 payments
  4. Kerecis GraftGuide $458 3 payments
  5. Kerecis SurgiClose Wound Care $458 3 payments
  6. Integra Recon-Skin And Wound $138 2 payments
  7. Integra Recon-Skin And Wound $138 2 payments
  8. INTEGRA DERMAL REGENERATION TEMPLATE $138 2 payments
  9. Integra Recon-Skin And Wound $120 1 payment
  10. PRIMATRIX $120 1 payment
  11. Other $226 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

240

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$8,304

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

23.3%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 84 $7,112
Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip Brand 15 $319
Ketoconazole Generic 14 $286
Doxycycline Hyclate Generic 38 $269
Ciprofloxacin Hcl Generic 24 $96
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 20 $76
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 21 $72
Clindamycin Hcl Generic 13 $42
Fluconazole Generic 11 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 115 billing codes

Paid by Medicare

$275,602

Medicare's payments for the services billed

Medicare patients

651

Average age 76

Services billed

4,775

292 women, 359 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 47%
Ischemic heart disease 31%
Diabetes 26%
Chronic kidney disease 23%
Atrial fibrillation 20%
Cancer 17%
Depression 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

14 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record